EP1082320A4 - Nouveaux composes d'imidazole substitue - Google Patents
Nouveaux composes d'imidazole substitueInfo
- Publication number
- EP1082320A4 EP1082320A4 EP99924480A EP99924480A EP1082320A4 EP 1082320 A4 EP1082320 A4 EP 1082320A4 EP 99924480 A EP99924480 A EP 99924480A EP 99924480 A EP99924480 A EP 99924480A EP 1082320 A4 EP1082320 A4 EP 1082320A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- imidazole compounds
- substituted imidazole
- novel substituted
- novel
- compounds
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Hospice & Palliative Care (AREA)
- Communicable Diseases (AREA)
- Transplantation (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Oncology (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US8664598P | 1998-05-26 | 1998-05-26 | |
US86645P | 1998-05-26 | ||
PCT/US1999/011455 WO1999061440A1 (fr) | 1998-05-26 | 1999-05-25 | Nouveaux composes d'imidazole substitue |
Publications (2)
Publication Number | Publication Date |
---|---|
EP1082320A1 EP1082320A1 (fr) | 2001-03-14 |
EP1082320A4 true EP1082320A4 (fr) | 2001-11-21 |
Family
ID=22199934
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP99924480A Withdrawn EP1082320A4 (fr) | 1998-05-26 | 1999-05-25 | Nouveaux composes d'imidazole substitue |
Country Status (4)
Country | Link |
---|---|
EP (1) | EP1082320A4 (fr) |
JP (1) | JP2002516325A (fr) |
CA (1) | CA2333157A1 (fr) |
WO (1) | WO1999061440A1 (fr) |
Families Citing this family (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU7966198A (en) | 1997-06-13 | 1998-12-30 | Smithkline Beecham Corporation | Novel pyrazole and pyrazoline substituted compounds |
US6610695B1 (en) | 1997-06-19 | 2003-08-26 | Smithkline Beecham Corporation | Aryloxy substituted pyrimidine imidazole compounds |
US6489325B1 (en) | 1998-07-01 | 2002-12-03 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US7301021B2 (en) | 1997-07-02 | 2007-11-27 | Smithkline Beecham Corporation | Substituted imidazole compounds |
US6562832B1 (en) | 1997-07-02 | 2003-05-13 | Smithkline Beecham Corporation | Substituted imidazole compounds |
EP1041989A4 (fr) | 1997-10-08 | 2002-11-20 | Smithkline Beecham Corp | Nouveaux composes substitues de cycloalcenyle |
CA2341370A1 (fr) | 1998-08-20 | 2000-03-02 | Smithkline Beecham Corporation | Nouveaux composes de triazole substitues |
JP2002532415A (ja) * | 1998-12-16 | 2002-10-02 | ワーナー−ランバート・カンパニー | Mek阻害剤による関節炎の治療 |
DE60015599T2 (de) | 1999-11-23 | 2005-11-03 | Smithkline Beecham Corp. | 3,4-DIHYDRO-(1H)CHINAZOLIN-2-ON-VERBINDUNGEN ALS CSBP/p38-KINASE-INHIBITOREN |
US6495582B1 (en) * | 2000-09-15 | 2002-12-17 | Vertex Pharmaceuticals Incorporated | Isoxazole compositions useful as inhibitors of ERK |
CA2440211A1 (fr) | 2001-03-09 | 2002-09-19 | Pfizer Products Inc. | Composes de benzimidazole anti-inflammatoires |
BR0207990A (pt) | 2001-03-09 | 2004-04-27 | Pfizer Prod Inc | Compostos antinflamatórios de triazolopiridinas |
DE60205974T2 (de) | 2001-04-04 | 2006-06-29 | Pfizer Products Inc., Groton | Neue Benzotriazole mit entzündungshemmender Wirkung |
AU2003245989A1 (en) | 2002-07-09 | 2004-01-23 | Boehringer Ingelheim Pharma Gmbh And Co. Kg | Pharmaceutical compositions of anticholinergics and p38 kinase inhibitors in the treatment of respiratory diseases |
EP1539121A4 (fr) * | 2002-08-29 | 2008-08-13 | Scios Inc | Methode pour favoriser l'osteogenese |
US7037923B2 (en) | 2002-08-30 | 2006-05-02 | Pfizer, Inc. | Alkyl-[4-(trifluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
US6949652B2 (en) | 2002-08-30 | 2005-09-27 | Pfizer, Inc. | Crystalline forms of 3-isopropyl-6-[4-(2,5-difluoro-phenyl)-oxazol-5-yl]-[1,2,4]triazolo-[4,3-A]pyridine |
PA8579601A1 (es) | 2002-08-30 | 2004-05-07 | Pfizer Prod Inc | Compuestos antiinflamatorios de di y trifloruro-triazolo-piridinas |
US7005523B2 (en) | 2002-08-30 | 2006-02-28 | Pfizer Inc. | Cycloalkyl-[4-(trifluorophenyl)-oxazol-5yl]-triazolo-pyridines |
US7012143B2 (en) | 2002-08-30 | 2006-03-14 | Dombroski Mark A | Cycloalkyl-[4-(difluorophenyl)-oxazol-5-yl]-triazolo-pyridines |
ES2324165T3 (es) * | 2003-02-26 | 2009-07-31 | Kowa Co., Ltd. | Tratamiento de la dermatitis alergica de contacto. |
US7244441B2 (en) | 2003-09-25 | 2007-07-17 | Scios, Inc. | Stents and intra-luminal prostheses containing map kinase inhibitors |
US20060035893A1 (en) | 2004-08-07 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Pharmaceutical compositions for treatment of respiratory and gastrointestinal disorders |
US20060166936A1 (en) * | 2004-10-29 | 2006-07-27 | Hayley Binch | Diaminotriazole compounds useful as inhibitors of protein kinases |
PE20060777A1 (es) | 2004-12-24 | 2006-10-06 | Boehringer Ingelheim Int | Derivados de indolinona para el tratamiento o la prevencion de enfermedades fibroticas |
EP1676574A3 (fr) | 2004-12-30 | 2006-07-26 | Johnson & Johnson Vision Care, Inc. | Procédé favorisant la survie des tissus ou cellules griffées |
EP1992344A1 (fr) | 2007-05-18 | 2008-11-19 | Institut Curie | P38 alpha comme cible therapeutique pour les maladies associées á une mutation de FGFR3 |
WO2010047793A2 (fr) | 2008-10-21 | 2010-04-29 | The General Hospital Corporation | Transplantation de cellules |
CA2759201A1 (fr) * | 2009-04-01 | 2010-10-07 | The Medical Research, Infrastructure, And Health Services Fund Of The Te L Aviv Medical Center | Procede de regulation de la proliferation et de la differenciation des keratinocytes |
EP2601299B1 (fr) | 2010-08-06 | 2019-04-24 | The General Hospital Corporation D/B/A Massachusetts General Hospital | Système et appareil de traitement cellulaire |
US20220213119A1 (en) | 2019-03-28 | 2022-07-07 | Jiangsu Hengrui Medicine Ca, Lid. | Thienoheterocyclic derivative, preparation method therefor and medical use thereof |
TW202102505A (zh) | 2019-03-29 | 2021-01-16 | 大陸商江蘇恆瑞醫藥股份有限公司 | 吡咯并雜環類衍生物、其製備方法及其在醫藥上的應用 |
US20220204512A1 (en) | 2019-05-24 | 2022-06-30 | Jiangsu Hengrui Medicine Co., Ltd. | Substituted fused bicyclic derivative, preparation method therefor, and application thereof in medicines |
JP2023543080A (ja) | 2020-09-29 | 2023-10-12 | 江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司 | ピロロ複素環系誘導体の結晶及びその製造方法 |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016230A1 (fr) * | 1996-10-17 | 1998-04-23 | Smithkline Beecham Corporation | Procedes permettant d'inhiber de maniere reversible la myelopoiese dans des tissus mammaliens |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5593992A (en) * | 1993-07-16 | 1997-01-14 | Smithkline Beecham Corporation | Compounds |
-
1999
- 1999-05-25 WO PCT/US1999/011455 patent/WO1999061440A1/fr not_active Application Discontinuation
- 1999-05-25 EP EP99924480A patent/EP1082320A4/fr not_active Withdrawn
- 1999-05-25 JP JP2000550846A patent/JP2002516325A/ja not_active Withdrawn
- 1999-05-25 CA CA002333157A patent/CA2333157A1/fr not_active Abandoned
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998016230A1 (fr) * | 1996-10-17 | 1998-04-23 | Smithkline Beecham Corporation | Procedes permettant d'inhiber de maniere reversible la myelopoiese dans des tissus mammaliens |
Non-Patent Citations (2)
Title |
---|
JACKSON J R ET AL: "Pharmacological Effects of SB 220025, a Selective Inhibitor of P38 Mitogen-Activated Protein Kinase, in Angiogenesis and Chronic Inflammatory Disease Models", JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, AMERICAN SOCIETY FOR PHARMACOLOGY AND, US, vol. 284, no. 2, 1998, pages 687 - 692, XP002134931, ISSN: 0022-3565 * |
See also references of WO9961440A1 * |
Also Published As
Publication number | Publication date |
---|---|
EP1082320A1 (fr) | 2001-03-14 |
WO1999061440A1 (fr) | 1999-12-02 |
CA2333157A1 (fr) | 1999-12-02 |
JP2002516325A (ja) | 2002-06-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1082320A4 (fr) | Nouveaux composes d'imidazole substitue | |
ZA985764B (en) | Novel substituted imidazole compounds | |
IL125282A0 (en) | Novel substituted imidazole compounds | |
IL133035A0 (en) | Novel substituted imidazole compounds | |
IL139732A0 (en) | Novel 2-alkyl substituted imidazole compounds | |
GB9801392D0 (en) | Novel compounds | |
PL346167A1 (en) | Novel compounds | |
AP9701008A0 (en) | Novel substituted imidazole compounds | |
SI0935465T1 (en) | Novel substituted imidazole compounds | |
AUPP484098A0 (en) | Novel imidazole compounds | |
AUPP735598A0 (en) | Novel imidazole compounds | |
GB9800337D0 (en) | Novel compounds | |
GB9802698D0 (en) | Novel compounds | |
GB9800289D0 (en) | Novel compounds | |
GB9800317D0 (en) | Novel compounds | |
GB9800324D0 (en) | Novel compounds | |
GB9802639D0 (en) | Novel compounds | |
GB9824027D0 (en) | Novel compounds | |
GB9802644D0 (en) | Novel compounds | |
GB9817826D0 (en) | Novel compounds | |
GB9814290D0 (en) | Novel compounds | |
GB9802807D0 (en) | Novel compounds | |
GB9802804D0 (en) | Novel compounds | |
GB9802801D0 (en) | Novel compounds | |
GB9802798D0 (en) | Novel compounds |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 20001222 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
A4 | Supplementary search report drawn up and despatched |
Effective date: 20011009 |
|
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE |
|
RIC1 | Information provided on ipc code assigned before grant |
Free format text: 7C 07D 403/14 A, 7C 07D 413/14 B, 7A 61K 31/505 B, 7A 61K 31/535 B, 7C 07D 403/04 B |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 20011221 |